Cue Biopharma
Astria Therapeutics

Inari Medical Announces First Patient Enrollment in PEERLESS II Randomized Controlled Trial (RCT)

November 27, 2023 | Last Trade: US$44.01 1.39 -3.06

IRVINE, Calif., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced the first patient enrollment in the PEERLESS II study. This prospective, global, multi-center randomized controlled trial (“RCT”) compares the outcomes of intermediate-risk acute pulmonary embolism (“PE”) patients treated with the FlowTriever® System against those treated with traditional anticoagulation therapy alone. The first patient was enrolled by Dr. William H. Matthai, Jr., Director of Clinical Cardiology Research and Professor of Clinical Medicine (Cardiovascular Medicine) at Penn Presbyterian Medical Center at the University of Pennsylvania.

"PEERLESS II is challenging the most commonly administered first-line therapy for PE around the world,” said Dr. Matthai. “Despite advances in mechanical thrombectomy, anticoagulation alone remains the standard of care. This trial aims to generate definitive evidence to influence PE treatment guidelines worldwide."

PEERLESS II is the largest study of its kind and will include up to 1,200 randomized patients at up to 100 global centers. The study is running alongside the currently enrolling PEERLESS RCT, which is comparing FlowTriever to catheter-directed thrombolysis. Both trials aim to generate the high-quality clinical evidence needed to move the field forward and establish FlowTriever as the optimal therapy for intermediate-risk PE patients.

"PE is a leading cause of cardiovascular death and this first patient enrollment represents an important milestone in the evolution of care for this disease,” added Global Principal Investigator Dr. Jay Giri, Director of the Cardiovascular Catheterization Laboratories Associate Director and Associate Professor of Medicine at the Hospital of the University of Pennsylvania. “The rigorous trial design, including meaningful patient-centric endpoints and independent adjudication of all safety events, lays the groundwork for this landmark study to impact future PE treatment decisions. Thank you to the PEERLESS II Steering Committee and clinical staff for helping us get the first patient enrolled."

"Inari is actively enrolling three RCTs: PEERLESS, PEERLESS II and DEFIANCE, demonstrating our relentless commitment to guideline-changing research aimed at ultimately improving patient outcomes,” said Dr. Thomas Tu, Inari’s Chief Medical Officer. “With the commitment of our dedicated investigators, we look forward to expedited enrollment to get us closer to changing the standard of care."

About the FlowTriever® System

The FlowTriever® system is 510(k)-cleared by FDA and CE marked for the non-surgical removal of clot from peripheral blood vessels, including for the use in the treatment of pulmonary embolism and clot in transit in the right atrium.

About Inari Medical, Inc.

Patients first. No small plans. Take care of each other. These are the guiding principles that form the ethos of Inari Medical. We are committed to improving lives in extraordinary ways by creating innovative solutions for both unmet and underrecognized health needs. In addition to our purpose-built products, we leverage our capabilities in education, clinical research, and program development to improve patient outcomes. We are passionate about our mission to establish our treatments as the standard of care for venous thromboembolism and beyond. We are just getting started.

Investor Contact:
John Hsu, CFA
VP, Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Image 1: PEERLESS II RCT Comparing Mechanical Thrombectomy to Conservative Medical ManagementImage 1

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...


Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...


End of content

No more pages to load

Next page